Chinese Hepatolgy ›› 2025, Vol. 30 ›› Issue (6): 876-881.
• Review • Previous Articles Next Articles
Received:2024-11-10
Online:2025-06-30
Published:2025-08-08
| [1] Song Y, Li C, Luo Y, et al. CCN6 improves hepatic steatosis, inflammation, and fibrosis in non-alcoholic steatohepatitis [J]. Liver Int, 2023, 43(2): 357-369. [2] Loomba R, Adams L A. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH [J]. Hepatology, 2019, 70(6): 1885-1888. [3] Hentze M W, Muckenthaler M U, Galy B, et al. Two to tango: regulation of Mammalian iron metabolism [J]. Cell, 2010, 142(1): 24-38. [4] Koskenkorva-Frank T S, Weiss G, Koppenol W H, et al. The complex interplay of iron metabolism, reactive oxygen species, and reactive nitrogen species: insights into the potential of various iron therapies to induce oxidative and nitrosative stress [J]. Free Radic Biol Med, 2013, 65: 1174-1194. [5] Czaja A J. Review article: iron disturbances in chronic liver diseases other than haemochromatosis - pathogenic, prognostic, and therapeutic implications [J]. Aliment Pharmacol Ther, 2019, 49(6): 681-701. [6] Yang Z, Wu J, Li X, et al. Association between dietary iron intake and the prevalence of nonalcoholic fatty liver disease: a cross-sectional study [J]. Medicine (Baltimore), 2019, 98(43): e17613. [7] Hernández-Aguilera A, Casacuberta N, Castañé H, et al. Nonalcoholic steatohepatitis modifies serum iron-related variables in patients with morbid obesity [J]. Biol Trace Elem Res, 2021, 199(12): 4555-4563. [8] Kowdley K V, Belt P, Wilson L A, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease [J]. Hepatology, 2012, 55(1): 77-85. [9] Wang J W, Jin C H, Ke J F, et al. Serum iron is closely associated with metabolic dysfunction-associated fatty liver disease in type 2 diabetes: a real-world study [J]. Front Endocrinol (Lausanne), 2022, 13: 942412. [10] Tong J, Lan X T, Zhang Z, et al. Ferroptosis inhibitor liproxstatin-1 alleviates metabolic dysfunction-associated fatty liver disease in mice: potential involvement of PANoptosis [J]. Acta Pharmacol Sin, 2023, 44(5): 1014-1028. [11] Gao H, Jin Z, Bandyopadhyay G, et al. Aberrant iron distribution via hepatocyte-stellate cell axis drives liver lipogenesis and fibrosis [J]. Cell Metab, 2022, 34(8): 1201-1213. e5. [12] Salaye L, Bychkova I, Sink S, et al. A low iron diet protects from steatohepatitis in a mouse model [J]. Nutrients, 2019, 11(9):2172. [13] Asrani S K, Devarbhavi H, Eaton J, et al. Burden of liver diseases in the world [J]. J Hepatol, 2019, 70(1): 151-171. [14] Friedman S L, Neuschwander-Tetri B A, Rinella M, et al. Mechanisms of NAFLD development and therapeutic strategies [J]. Nat Med, 2018, 24(7): 908-922. [15] Tan L, Zhou Q, Liu J, et al. Association of iron status with non-alcoholic fatty liver disease and liver fibrosis in US adults: a cross-sectional study from NHANES 2017-2018 [J]. Food Funct, 2023, 14(12): 5653-5662. [16] Moreno-Navarrete J M, Novelle M G, Catalán V, et al. Insulin resistance modulates iron-related proteins in adipose tissue [J]. Diabetes Care, 2014, 37(4): 1092-1100. [17] Krisai P, Leib S, Aeschbacher S, et al. Relationships of iron metabolism with insulin resistance and glucose levels in young and healthy adults [J]. Eur J Intern Med, 2016, 32: 31-37. [18] Altamura S, Müdder K, Schlotterer A, et al. Iron aggravates hepatic insulin resistance in the absence of inflammation in a novel db/db mouse model with iron overload [J]. Mol Metab, 2021, 51: 101235. [19] Varghese J, James J V, Anand R, et al. Development of insulin resistance preceded major changes in iron homeostasis in mice fed a high-fat diet [J]. J Nutr Biochem, 2020, 84: 108441. [20] Britton L J, Subramaniam V N, Crawford D H. Iron and non-alcoholic fatty liver disease [J]. World J Gastroenterol, 2016, 22(36): 8112-8122. [21] Lee Y S, Hwang L C. The association between different obesity phenotypes and liver fibrosis scores in elderly individuals with fatty liver in Taiwan [J]. Diabetes Metab Syndr Obes, 2021, 14: 1473-1483. [22] Zhao X, Ma Y, Shi M, et al. Excessive iron inhibits insulin secretion via perturbing transcriptional regulation of SYT7 by OGG1 [J]. Cell Mol Life Sci, 2023, 80(6): 159. [23] Jiang X, Stockwell B R. Ferroptosis: mechanisms, biology and role in disease [J]. Nat Rev Mol Cell Biol, 2021, 22(4): 266-282. [24] Nassir F. NAFLD: mechanisms, treatments, and biomarkers [J]. Biomolecules, 2022, 12(6):824. [25] Commoner B, Townsend J, Pake G E. Free radicals in biological materials [J]. Nature, 1954, 174(4432): 689-691. [26] Chen Z, Tian R, She Z, et al. Role of oxidative stress in the pathogenesis of nonalcoholic fatty liver disease [J]. Free Radic Biol Med, 2020, 152: 116-141. [27] Tsurusaki S, Tsuchiya Y, Koumura T, et al. Hepatic ferroptosis plays an important role as the trigger for initiating inflammation in nonalcoholic steatohepatitis [J]. Cell Death Dis, 2019, 10(6): 449. [28] Li X, Wang T X, Huang X, et al. Targeting ferroptosis alleviates methionine-choline deficient (MCD)-diet induced NASH by suppressing liver lipotoxicity [J]. Liver Int, 2020, 40(6): 1378-1394. [29] Khanmohammadi S, Kuchay M S. Toll-like receptors and metabolic (dysfunction)-associated fatty liver disease [J]. Pharmacol Res, 2022, 185: 106507. [30] Masarone M, Rosato V, Dallio M, et al. Role of oxidative stress in pathophysiology of nonalcoholic fatty liver disease [J]. Oxid Med Cell Longev, 2018, 2018: 9547613. [31] Pietrangelo A. Hereditary hemochromatosis: pathogenesis, diagnosis, and treatment [J]. Gastroenterology, 2010, 139(2): 393-408, 408.e391-e392. [32] Von Krusenstiern A N, Robson R N. Identification of essential sites of lipid peroxidation in ferroptosis [J]. Nat Chem Biol, 2023, 19(6): 719-730. [33] Podszun M C, Chung J Y. 4-HNE immunohistochemistry and image analysis for detection of lipid peroxidation in human liver samples using vitamin E treatment in NAFLD as a proof of concept [J]. J Histochem Cytochem, 2020, 68(9): 635-643. [34] Bellanti F, Villani R, Facciorusso A, et al. Lipid oxidation products in the pathogenesis of non-alcoholic steatohepatitis [J]. Free Radic Biol Med, 2017, 111: 173-185. [35] Doll S, Freitas F P, Shah R, et al. FSP1 is a glutathione-independent ferroptosis suppressor [J]. Nature, 2019, 575(7784): 693-698. [36] Qi J, Kim J W, Zhou Z, et al. Ferroptosis affects the progression of nonalcoholic steatohepatitis via the modulation of lipid peroxidation-mediated cell death in mice [J]. Am J Pathol, 2020, 190(1): 68-81. [37] Xue J, Yu C, Sheng W, et al. The Nrf2/GCH1/BH4 axis ameliorates radiation-induced skin injury by modulating the ROS cascade [J]. J Invest Dermatol, 2017, 137(10): 2059-2068. [38] Day K, Seale L A, Graham R M, et al. Selenotranscriptome network in non-alcoholic fatty liver disease [J]. Front Nutr, 2021, 8: 744825. [39] Ingold I, Berndt C, Schmitt S, et al. Selenium utilization by GPX4 is required to prevent hydroperoxide-induced ferroptosis [J]. Cell, 2018, 172(3): 409-422.e421. [40] Wang S, Liu Z, Geng J, et al. An overview of ferroptosis in non-alcoholic fatty liver disease [J]. Biomed Pharmacother, 2022, 153: 113374. [41] Zhu Z, Zhang Y, Huang X, et al. Thymosin beta 4 alleviates non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4 [J]. Eur J Pharmacol, 2021, 908: 174351. [42] Zhang J, Xie H, Yao J, et al. TRIM59 promotes steatosis and ferroptosis in non-alcoholic fatty liver disease via enhancing GPX4 ubiquitination [J]. Hum Cell, 2023, 36(1): 209-222. [43] Tong J, Li D, Meng H, et al. Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease [J]. Acta Pharm Sin B, 2022, 12(9): 3650-3666. [44] Valenti L, Fracanzani A L, Dongiovanni P, et al. Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study [J]. Am J Gastroenterol, 2007, 102(6): 1251-1258. [45] Beaton M D, Chakrabarti S, Levstik M, et al. Phase Ⅱ clinical trial of phlebotomy for non-alcoholic fatty liver disease [J]. Aliment Pharmacol Ther, 2013, 37(7): 720-729. [46] Kanamori Y, Tanaka M, Itoh M, et al. Iron-rich Kupffer cells exhibit phenotypic changes during the development of liver fibrosis in NASH [J]. iScience, 2021, 24(2): 102032. [47] Kaji K, Yoshiji H, Kitade M, et al. Combination treatment of angiotensin Ⅱ type Ⅰ receptor blocker and new oral iron chelator attenuates progression of nonalcoholic steatohepatitis in rats [J]. Am J Physiol Gastrointest Liver Physiol, 2011, 300(6): G1094-G1104. [48] Chen K, Chen X, Xue H, et al. Coenzyme Q10 attenuates high-fat diet-induced non-alcoholic fatty liver disease through activation of the AMPK pathway [J]. Food Funct, 2019, 10(2): 814-823. [49] Jiang J X, Tomilov A, Montgomery C. Shc inhibitor idebenone ameliorates liver injury and fibrosis in dietary NASH in mice [J]. J Biochem Mol Toxicol, 2021, 35(10): e22876. [50] Imai H, Matsuoka M, Kumagai T, et al. Lipid peroxidation-dependent cell death regulated by GPx4 and ferroptosis [J]. Curr Top Microbiol Immunol, 2017, 403: 143-170. [51] Bell L N, Wang J, Muralidharan S, et al. Relationship between adipose tissue insulin resistance and liver histology in nonalcoholic steatohepatitis: a pioglitazone versus vitamin E versus placebo for the treatment of nondiabetic patients with nonalcoholic steatohepatitis trial follow-up study [J]. Hepatology, 2012, 56(4): 1311-1318. [52] Bril F, Cusi K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes: a call to action [J]. Diabetes Care, 2017, 40(3): 419-430. [53] Luo Y, Chen H, Liu H, et al. Protective effects of ferroptosis inhibition on high fat diet-induced liver and renal injury in mice [J]. Int J Clin Exp Pathol, 2020, 13(8): 2041-2049. [54] Wu A, Feng B, Yu J, et al. Fibroblast growth factor 21 attenuates iron overload-induced liver injury and fibrosis by inhibiting ferroptosis [J]. Redox Biol, 2021, 46: 102131. [55] Diehl A M, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis [J]. N Engl J Med, 2017, 377(21): 2063-2072. [56] Zhu X, Xiong T, Liu P, et al. Quercetin ameliorates HFD-induced NAFLD by promoting hepatic VLDL assembly and lipophagy via the IRE1a/XBP1s pathway [J]. Food Chem Toxicol, 2018, 114: 52-60. [57] Qin G, Ma J, Huang Q, et al. Isoquercetin improves hepatic lipid accumulation by activating AMPK pathway and suppressing TGF-β signaling on an HFD-Induced nonalcoholic fatty liver disease rat model [J]. Int J Mol Sci, 2018, 19(12):4126. [58] Wang Z X, Ma J, Li X Y, et al. Quercetin induces p53-independent cancer cell death through lysosome activation by the transcription factor EB and reactive oxygen species-dependent ferroptosis [J]. Br J Pharmacol, 2021, 178(5): 1133-1148. [59] Buniatian G H. Stages of activation of hepatic stellate cells: effects of ellagic acid, an inhibiter of liver fibrosis, on their differentiation in culture [J]. Cell Prolif, 2003, 36(6): 307-319. [60] Li L, Wang K, Jia R, et al. Ferroportin-dependent ferroptosis induced by ellagic acid retards liver fibrosis by impairing the SNARE complexes formation [J]. Redox Biol, 2022, 56: 102435. [61] Kong Z, Liu R, Cheng Y. Artesunate alleviates liver fibrosis by regulating ferroptosis signaling pathway [J]. Biomed Pharmacother, 2019, 109: 2043-2053. [62] Hassannia B, Vandenabeele P, Vanden Berghe T. Targeting ferroptosis to iron out cancer [J]. Cancer Cell, 2019, 35(6): 830-849. [63] Kinoshita H, Okabe H, Beppu T, et al. Cystine/glutamic acid transporter is a novel marker for predicting poor survival in patients with hepatocellular carcinoma [J]. Oncol Rep, 2013, 29(2): 685-689. |
| No related articles found! |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
